TRV GP IV, LLC

CIK 1688325 · View on SEC EDGAR ↗

Portfolio value
$253.7M
#5,695 of 9,443 by 13F value · top 60.3%
Positions
2
As of
June 30, 2026

Portfolio value QoQ: -5.0% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
2
Effective number of positions
2.0

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 0.0% Est. buys $0 · sells $0

Median holding: 6.0 quarters Tracked Q4 2024–Q2 2026 · 66.7% still held

New positions
0
Increased
0
Decreased
0
Closed
1
On this page

Performance vs S&P 500

Tracked Q4 2024–Q2 2026
+110.1%
S&P 500 total return (same window)
+28.1%
Excess return
+82.1%

Annualized: +64.3% · S&P 500: +18.0%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Healthcare
100.0%

Full portfolio 2 positions

Type Streak 8Q trend
MAZE Maze Therapeutics, Inc. - Common Stock $133,502,907 52.63% 4,473,958 $-44,739
TNGX Tango Therapeutics, Inc. - Common Stock $120,181,383 47.37% 6,374,574 $-13,174,705

Top movers (QoQ)

Security Action Shares Δ Value Δ
TNGX Price move only +0 -$13.2M
MAZE Price move only +0 -$45K

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
PLRX Sept. 30, 2025 2,132,867 $2,474,126 -19.9%